EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Nanoliposomal Irinotecan in Combination With 5‐Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum‐Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial

Muh-Hwa Yang iD, Shang-Yin Wu, I-Wei Ho, Nai-Jung Chiang, Chin-Fu Hsaio, Chen-Yuan Lin, Ming-Yu Lien, Peter Mu-Hsin Chang, Jia-Hong Chen, Ching-Yun Hsieh, Ruey-Long Hong, Chao-Tung Lee und 4 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.71307 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2025. Verfasst von Muh-Hwa Yang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Irinotecan, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taiwan Minstry of Science and Technology, National Health Research Institutes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the efficacy and safety of nanoliposomal irinotecan (nal‐IRI) plus 5‐fluorouracil (5‐FU) and leucovorin (LV) in patients with platinum‐refractory or intolerant head and neck squamous cell carcinoma (HNSCC) and esophageal squamous cell carcinoma (ESCC).

Methods

In this multicenter, phase 2 study (NCT03712397), patients with advanced HNSCC ( n = 43) or ESCC ( n = 16) who had failed or were intolerant to platinum‐based chemotherapy received biweekly nal‐IRI 80 mg/m 2 (equivalent to 70 mg/m 2 of irinotecan base), LV 400 mg/m 2 , and 5‐FU 2400 mg/m 2 until progression or unacceptable toxicity. The primary endpoint was the objective response rate (ORR).

Results

In the intent‐to‐treat analysis, the ORR and disease control rate were 8.5% and 59.3% for the entire group. In the HNSCC subgroup, ORR and disease control rate were 11.6% and 65.1%, with a median progression‐free survival (PFS) of 2.7 months and an overall survival (OS) of 8.1 months. By contrast, no objective responses were observed in ESCC (ORR 0%, disease control rate 43.8%, median OS 4.2 months). The most common grade 3/4 toxicities were lymphopenia (50.8%), neutropenia (42.4%), leukopenia (33.9%), anemia (28.8%), and anorexia (8.5%).

Conclusions

Nal‐IRI/5‐FU/LV demonstrates modest activity with acceptable safety profiles in patients with platinum‐refractory or intolerable advanced HNSCC. The exploratory findings warrant confirmation in larger, randomized studies. Trial Registration ClinicalTrials.gov : NCT03712397

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsIrinotecanEsophageal Squamous Cell CarcinomaEsophageal NeoplasmsSquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsHumansMaleFluorouracilFemaleMiddle AgedLeucovorinAgedLiposomesAdultChemoradiotherapy

Stichwörter der Autor:innen

esophageal cancerhead and neck cancernanoliposomal irinotecanplatinumsquamous cell carcinoma

Substanzen

FluorouracilLeucovorinIrinotecanLiposomes

Autor:innen und Institutionen

  • Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan.
  • Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan.

ORCID-Profile: Muh-Hwa Yang, Li-Tzong Chen, Li-Yuan Bai

Förderung

  • Taiwan Minstry of Science and Technology
  • National Health Research Institutes

Zitieren

APA

Yang, M. H., Wu, S. Y., Ho, I. W., Chiang, N. J., Hsaio, C. F., Lin, C. Y., Lien, M. Y., Chang, P. M., Chen, J. H., Hsieh, C. Y., Hong, R. L., Lee, C. T., Chen, L. T., Liu, T. W., Chiu, C. F., & Bai, L. Y. (2025). Nanoliposomal Irinotecan in Combination With 5‐Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum‐Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial. Cancer Medicine. https://doi.org/10.1002/cam4.71307

Vancouver

Yang MH, Wu SY, Ho IW, Chiang NJ, Hsaio CF, Lin CY, et al. Nanoliposomal Irinotecan in Combination With 5‐Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum‐Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial. Cancer Medicine. 2025. doi:10.1002/cam4.71307

BibTeX
@article{Yang2025,
  author = {Yang, Muh-Hwa and Wu, Shang-Yin and Ho, I-Wei and Chiang, Nai-Jung and Hsaio, Chin-Fu and Lin, Chen-Yuan and Lien, Ming-Yu and Chang, Peter Mu-Hsin and Chen, Jia-Hong and Hsieh, Ching-Yun and Hong, Ruey-Long and Lee, Chao-Tung and Chen, Li-Tzong and Liu, Tsang-Wu and Chiu, Chang-Fang and Bai, Li-Yuan},
  title = {Nanoliposomal Irinotecan in Combination With 5‐Fluorouracil and Leucovorin for Advanced Head and Neck and Esophageal Squamous Cell Carcinoma After Prior Platinum‐Based Chemotherapy or Chemoradiotherapy: A Multicenter Phase II Trial},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71307}
}
Kostenlos starten →